Page last updated: 2024-08-05 15:32:38
antileishmanial agent
An antiprotozoal drug used to treat or prevent infections caused by protozoan parasites that belong to the genus Leishmania.
ChEBI ID: 70868
Members (17)
| Member | Definition | Class |
|---|---|---|
| 5-o-methylembelin | A member of the class of monohydroxy-1,4-benzoquinones that is embelin in which the hydroxy group at position 5 is replaced by a methoxy group. Isolated from Lysimachia punctata and Embelia ribes, it exhibits antileishmanial activity as well as inhibitory activity towards hepatitis C protease. | 5-O-methyl embelin |
| 5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4h-1-benzopyran-4-one | A member of the class of chromones that is 4H-chromen-4-one in which the hydrogens at positions 2,5,7 and 8 are replaced by methyl, hydroxy, hydroxy, and (3S,4R)-3-hydroxy-1-methylpiperidin-4-yl groups, respectively. It is an alkaloid initially isolated from Amoora rohituka and is a precursor of the anti-cancer compound flavopiridol. | rohitukine |
| acivicin | An L-alpha-amino acid that is L-alanine in which the methyl group is replaced by a (5S)-3-chloro-4,5-dihydro-1,2-oxazol-5-yl group. A glutamine analogue antimetabolite, it interferes with glutamate metabolism and several glutamate-dependent synthetic enzymes. It is obtained as a fermentation product of Streptomyces sviceus bacteria. | acivicin |
| acteoside | A glycoside that is the alpha-L-rhamnosyl-(1->3)-beta-D-glucoside of hydroxytyrosol in which the hydroxy group at position 4 of the glucopyranosyl moiety has undergone esterification by formal condensation with trans-caffeic acid. | acteoside |
| ancistroealaine a | An isoquinoline alkaloid that is (3S)-6,8-dimethoxy-1,3-dimethyl-3,4-dihydroisoquinoline substituted by a 4,5-dimethoxy-7-methylnaphthalen-1-yl group at position 5. It is isolated from the leaves of Ancistrocladus tanzaniensis and exhibits antiplasmodial, antileishmanial and antitrypanocidal activities. | ancistrotanzanine B |
| ascaridole | A p-menthane monoterpenoid that is p-menth-2-ene with a peroxy group across position 1 to 4. | ascaridole |
| carbobenzoxyvalylphenylalanine aldehyde | A dipeptide resulting from the formal condensation of the carboxy group of N-benzyloxycarbonyl-L-valine with the amino group of L-phenylalanine aldehyde. It is a potent cell-permeable inhibitor of calpain I and II, and is also a gamma-secretase inhibitor. | Z-Val-Phe-H |
| ciliatamide a | A lipopeptide that contains N-methylphenylalanine and lysine as the amino acid residues linked to a dec-9-enoyl moiety via an amide linkage (the R,R stereoisomer). It is isolated from the deep sea sponge Aaptos ciliata and exhibits antileishmanial activity. | ciliatamide A |
| coronardine | A monoterpenoid indole alkaloid with formula C21H26N2O2. It is isolated from the flowering plant genus, Tabernaemontana. | (-)-coronaridine |
| dehydroemetine | A pyridoisoquinoline which was developed in response to the cardiovascular toxicity associated with emetine and results from the dehydrogenation of the heterotricylic ring of emetine. It is an antiprotozoal agent and displays antimalarial, antiamoebic, and antileishmanial properties. | dehydroemetine |
| dihydrobetulinic acid | A pentacyclic triterpenoid that is lupane having a 3beta-hydroxy and 28-carboxy substituents. Isolated from the leaves of Syzygium claviflorum, it exhibits anti-HIV and antileishmanial activity. | dihydrobetulinic acid |
| flavokawain b | A member of the class of chalcones that consists of trans-chalcone substituted by hydroxy group at positions 2' and methoxy groups at positions 4' and 6'. Isolated from Piper methysticum and Piper rusbyi, it exhibits antileishmanial, anti-inflammatory and antineoplastic activities. | flavokawain B |
| monastrol | A racemate comprising equimolar amounts of R- and S-monastrol. | ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate; monastrol |
| physalin f | A physalin with antimalarial and antitumour activities isolated from Physalis angulata. | physalin F |
| quercitrin | A quercetin O-glycoside that is quercetin substituted by a alpha-L-rhamnosyl moiety at position 3 via a glycosidic linkage. | quercitrin |
| ravuconazole | A member of the class of triazoles that is 1-butyl-1H-1,2,4-triazole in which the butyl group is substituted at positions 2, 2, and 3 by hydroxy, 2,4-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively (the R,R stereoisomer). It exhibits antifungal activity by inhibition of 14alpha demethylase, an enzyme involved in sterol synthesis, resulting in lysis of the fungal cell wall and fungal cell death. (NCIO4) | ravuconazole |
| rocaglamide | An organic heterotricyclic compound that is 2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan substituted by hydroxy groups at positions 1 and 8b, methoxy groups at positions 6 and 8, a 4-methoxyphenyl group at position 3a, a phenyl group at position 3 and a N,N-dimethylcarbamoyl group at position 1. Isolated from Aglaia odorata and Aglaia duperreana, it exhibits antineoplastic activity. | rocaglamide |
Research
Studies (1,836)
| Timeframe | Studies, Drugs with This Role(%) | All Drugs % |
|---|---|---|
| pre-1990 | 214 (11.66) | 18.7374 |
| 1990's | 258 (14.05) | 18.2507 |
| 2000's | 458 (24.95) | 29.6817 |
| 2010's | 695 (37.85) | 24.3611 |
| 2020's | 211 (11.49) | 2.80 |
Study Types
| Publication Type | Studies, Drugs with this Role (%) | All Drugs (%) |
|---|---|---|
| Trials | 31 (1.60%) | 5.53% |
| Reviews | 66 (3.41%) | 6.00% |
| Case Studies | 10 (0.52%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 1,829 (94.47%) | 84.16% |
Protein Targets (147)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| 67.9K protein | Vaccinia virus | Potency | 8.2962 | 2 | 6 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 11.7546 | 1 | 2 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 7.4598 | 1 | 2 |
| AR protein | Homo sapiens (human) | Potency | 9.0560 | 3 | 3 |
| arylsulfatase A | Homo sapiens (human) | Potency | 2.3934 | 1 | 1 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 20.5878 | 1 | 1 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 3.7485 | 3 | 3 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 0.0004 | 2 | 2 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 14.1254 | 1 | 1 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 3.7255 | 2 | 2 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 0.0316 | 2 | 2 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 25.8631 | 1 | 3 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 22.3872 | 1 | 1 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 29.8816 | 1 | 2 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 6.7033 | 2 | 8 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 6.6824 | 1 | 1 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 2.0595 | 1 | 1 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 20.0462 | 1 | 2 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 45.3688 | 2 | 3 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 30.2779 | 1 | 3 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 19.0047 | 3 | 3 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 15.5686 | 3 | 3 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 41.4568 | 1 | 2 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 0.1163 | 4 | 4 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 64.4679 | 1 | 2 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 0.3317 | 1 | 1 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 6.0936 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 6.0936 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 6.0936 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 6.0936 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 6.0936 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 6.0936 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 6.0936 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 6.0936 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 6.0936 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 6.0936 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 6.0936 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 6.0936 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 6.0936 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 6.0936 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 6.0936 | 1 | 5 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 6.0936 | 1 | 5 |
| geminin | Homo sapiens (human) | Potency | 18.7291 | 3 | 6 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| GLS protein | Homo sapiens (human) | Potency | 28.9342 | 1 | 2 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 2.5119 | 1 | 1 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 29.0929 | 1 | 1 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 16.1936 | 1 | 2 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 29.8816 | 1 | 6 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 1 | 2 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 17.7828 | 1 | 1 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 30.7410 | 3 | 3 |
| IDH1 | Homo sapiens (human) | Potency | 14.5497 | 1 | 2 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 39.6058 | 2 | 2 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 18.8541 | 2 | 2 |
| lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 17.9008 | 1 | 2 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 10.6910 | 1 | 1 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 56.2341 | 1 | 1 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 12.0627 | 1 | 2 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 0.0141 | 1 | 1 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 1.7783 | 2 | 2 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 11.2202 | 1 | 1 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 0.0176 | 2 | 2 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 24.8033 | 2 | 2 |
| P53 | Homo sapiens (human) | Potency | 22.3872 | 1 | 1 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 50.1187 | 1 | 1 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 10.6910 | 1 | 1 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 8.9125 | 1 | 1 |
| polyprotein | Zika virus | Potency | 0.3317 | 1 | 1 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 63.0957 | 1 | 1 |
| serine-protein kinase ATM isoform a | Homo sapiens (human) | Potency | 28.1838 | 1 | 1 |
| Smad3 | Homo sapiens (human) | Potency | 28.1838 | 1 | 1 |
| snurportin-1 | Homo sapiens (human) | Potency | 39.6058 | 2 | 2 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| TDP1 protein | Homo sapiens (human) | Potency | 16.7356 | 2 | 11 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 22.5848 | 1 | 2 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 2.9849 | 2 | 2 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 1.5849 | 1 | 1 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 8.9125 | 1 | 1 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 8.9125 | 1 | 1 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 56.2341 | 1 | 1 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 49.3386 | 1 | 3 |
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | IC50 | 0.3000 | 1 | 1 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | IC50 | 2,000.0000 | 1 | 1 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | IC50 | 2,000.0000 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Bos taurus (cattle) | IC50 | 10.0000 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | IC50 | 1.0750 | 2 | 2 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | IC50 | 0.1200 | 2 | 3 |
| Aldo-keto reductase family 1 member C21 | Mus musculus (house mouse) | IC50 | 33.3000 | 1 | 1 |
| Arginase | Leishmania amazonensis | IC50 | 12.2000 | 1 | 1 |
| Arginase | Leishmania amazonensis | Ki | 4.3000 | 2 | 2 |
| Aurora kinase A | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | IC50 | 11.8000 | 1 | 1 |
| Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | Ki | 39.6000 | 1 | 1 |
| Calpain-1 catalytic subunit | Homo sapiens (human) | IC50 | 0.3000 | 1 | 1 |
| Calpain-1 catalytic subunit | Homo sapiens (human) | Ki | 0.0080 | 1 | 1 |
| Calpain-1 catalytic subunit | Sus scrofa (pig) | Ki | 0.0100 | 1 | 1 |
| Cathepsin B | Homo sapiens (human) | Ki | 0.0240 | 1 | 1 |
| Chymotrypsinogen A | Bos taurus (cattle) | Ki | 54.0000 | 1 | 1 |
| Cyclin-A2 | Homo sapiens (human) | IC50 | 7.3000 | 3 | 3 |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | IC50 | 7.3000 | 3 | 3 |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | IC50 | 0.3000 | 3 | 3 |
| Cyclin-T1 | Homo sapiens (human) | IC50 | 0.3000 | 3 | 3 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 1.0100 | 1 | 1 |
| Eukaryotic initiation factor 4A-I | Homo sapiens (human) | IC50 | 0.1044 | 4 | 4 |
| Integrase | Human immunodeficiency virus 1 | IC50 | 7.8000 | 1 | 1 |
| integrase, partial | Human immunodeficiency virus 1 | IC50 | 12.4198 | 2 | 4 |
| Kinesin-like protein KIF11 | Homo sapiens (human) | IC50 | 12.8247 | 9 | 9 |
| Kinesin-like protein KIFC1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | IC50 | 12.4198 | 2 | 4 |
| Macrophage-expressed gene 1 protein | Homo sapiens (human) | IC50 | 9.1000 | 1 | 1 |
| Mitogen-activated protein kinase 10 | Homo sapiens (human) | IC50 | 24.1500 | 1 | 2 |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | IC50 | 24.1500 | 1 | 2 |
| Neuraminidase | Influenza A virus (A/USSR/90/1977(H1N1)) | IC50 | 115.1000 | 2 | 2 |
| NF-kappa-B inhibitor alpha | Homo sapiens (human) | IC50 | 27.1000 | 1 | 1 |
| Non-structural protein 1 | Dengue virus | IC50 | 1.7000 | 1 | 1 |
| Nuclear factor NF-kappa-B p105 subunit | Homo sapiens (human) | IC50 | 1.0375 | 2 | 2 |
| Polyphenol oxidase 2 | Agaricus bisporus | IC50 | 125.0000 | 2 | 2 |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | IC50 | 1.9267 | 3 | 3 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 10.3700 | 1 | 1 |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | IC50 | 2,000.0000 | 3 | 3 |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | IC50 | 1,337.1000 | 3 | 3 |
| Protein kinase C alpha type | Homo sapiens (human) | IC50 | 9.3000 | 1 | 1 |
| Protein kinase C alpha type | Rattus norvegicus (Norway rat) | IC50 | 15.3560 | 3 | 3 |
| Protein kinase C alpha type | Rattus norvegicus (Norway rat) | Ki | 25.0000 | 2 | 2 |
| Protein kinase C beta type | Rattus norvegicus (Norway rat) | IC50 | 15.3560 | 3 | 3 |
| Protein kinase C beta type | Rattus norvegicus (Norway rat) | Ki | 25.0000 | 2 | 2 |
| Protein kinase C delta type | Rattus norvegicus (Norway rat) | IC50 | 15.3560 | 3 | 3 |
| Protein kinase C delta type | Rattus norvegicus (Norway rat) | Ki | 25.0000 | 2 | 2 |
| Protein kinase C epsilon type | Rattus norvegicus (Norway rat) | IC50 | 15.3560 | 3 | 3 |
| Protein kinase C epsilon type | Rattus norvegicus (Norway rat) | Ki | 25.0000 | 2 | 2 |
| Protein kinase C eta type | Rattus norvegicus (Norway rat) | IC50 | 15.3560 | 3 | 3 |
| Protein kinase C eta type | Rattus norvegicus (Norway rat) | Ki | 25.0000 | 2 | 2 |
| Protein kinase C gamma type | Rattus norvegicus (Norway rat) | IC50 | 15.3560 | 3 | 3 |
| Protein kinase C gamma type | Rattus norvegicus (Norway rat) | Ki | 25.0000 | 2 | 2 |
| Protein kinase C theta type | Rattus norvegicus (Norway rat) | IC50 | 15.3560 | 3 | 3 |
| Protein kinase C theta type | Rattus norvegicus (Norway rat) | Ki | 25.0000 | 2 | 2 |
| Protein kinase C zeta type | Rattus norvegicus (Norway rat) | IC50 | 15.3560 | 3 | 3 |
| Protein kinase C zeta type | Rattus norvegicus (Norway rat) | Ki | 25.0000 | 2 | 2 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 | 12.2700 | 2 | 2 |
| Serine/threonine-protein kinase pim-2 | Homo sapiens (human) | IC50 | 25.0000 | 1 | 1 |
| Transcription factor p65 | Homo sapiens (human) | IC50 | 0.7367 | 6 | 6 |
| Urease | Canavalia ensiformis (jack bean) | Ki | 25.6600 | 1 | 1 |
| Urease subunit alpha | Helicobacter pylori 26695 | IC50 | 1,220.0000 | 1 | 1 |
| Urease subunit beta | Helicobacter pylori 26695 | IC50 | 1,220.0000 | 1 | 1 |
| Xanthine dehydrogenase/oxidase | Homo sapiens (human) | IC50 | 57.3700 | 2 | 2 |
| Zinc finger protein GLI1 | Homo sapiens (human) | IC50 | 0.6600 | 1 | 1 |
Activation Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| Eukaryotic initiation factor 4A-I | Homo sapiens (human) | Kd | 0.1560 | 1 | 1 |
Other Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| Arginase | Leishmania amazonensis | Kis | 7.2000 | 1 | 1 |
| glycogen synthase kinase-3 alpha | Homo sapiens (human) | AC50 | 29.7700 | 1 | 1 |
| Nuclear factor NF-kappa-B p105 subunit | Homo sapiens (human) | ED50 | 2.0000 | 1 | 1 |
| Prolyl 4-hydroxylase, beta polypeptide | Homo sapiens (human) | AC50 | 2.4800 | 2 | 2 |
| Transcription factor p65 | Homo sapiens (human) | ED50 | 0.0800 | 1 | 1 |